Collagen Solutions PLC AGM Statement (2184P)
August 30 2017 - 2:00AM
UK Regulatory
TIDMCOS
RNS Number : 2184P
Collagen Solutions PLC
30 August 2017
Collagen Solutions Plc
(the "Company" or the "Group")
AGM Statement
Collagen Solutions plc (AIM: COS), the developer and
manufacturer of medical grade collagen components for use in
regenerative medicine, medical devices and in-vitro diagnostics,
will hold its Annual General Meeting at 11am today at their offices
at 3 Robroyston Oval, Nova Business Park, Glasgow, G33 1AP. At the
meeting, Jamal Rushdy, CEO of Collagen Solutions will make the
following statement:
"I am pleased to highlight our recent progress with respect to
our key initiatives for this fiscal year. First, we have now
enrolled 12 of 15 (80%) of the patients scheduled in the open label
extension study for ChondroMimetic(R), an osteochondral scaffold
for the repair of cartilage defects in the knee. We expect final
data collection and analysis by the end of the calendar year, with
a submission for CE-mark certification to follow. We have
strengthened our tissue business by recently expanding our abattoir
capacity by approximately 80%, and additional abattoir
qualifications and yield improvement initiatives are in process.
Our core business momentum is continuing with four new early-stage
customer deals in the first quarter of the fiscal year, including
two new tissue customers. This new business will help underpin our
overall anticipated growth which is weighted to the second half of
our fiscal year. Finally, our U.S. facility consolidation plans are
on track, which will provide improved collaboration and
cost-savings to be used for further R&D investment. We expect
to merge these sites next month in our new facility near
Minneapolis, Minnesota."
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and
manufacturer of medical grade collagen, tissues, and related
medical devices and components for use in regenerative medicine,
medical devices and in-vitro diagnostics and research. The Company
is also expanding its range of biomaterials-based finished medical
devices based on its internal and acquired intellectual property
for commercialisation with partners via licensing and distribution
arrangements, including ChondroMimetic(R), an osteochondral
scaffold for repairing cartilage defects in the knee. The Company's
products are used in a wide variety of applications including
orthopedics, cardiovascular, dental, plastic surgery, wound
healing, neurology and urology.
For more information, visit www.collagensolutions.com
Enquiries:
Collagen Solutions Plc Contact via Walbrook
Jamal Rushdy, Chief Executive
Officer
Gill Black, Chief Financial
Officer
Cenkos Securities plc (Nominated Tel: 0207 397 8900
Adviser and Broker)
Stephen Keys
Steve Cox
Walbrook PR Tel: 020 7933 8780 or collagen@walbrookpr.com
Mike Wort Mob: 07900 608 002
Anna Dunphy Mob: 07876 741 001
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMEASPNAEDXEFF
(END) Dow Jones Newswires
August 30, 2017 02:00 ET (06:00 GMT)
Collagen Solutions (LSE:COS)
Historical Stock Chart
From Apr 2024 to May 2024
Collagen Solutions (LSE:COS)
Historical Stock Chart
From May 2023 to May 2024